A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women

References

• Jokinen K, Rautava P, Makinen J, et al. Experience of climacteric symptoms among 42–46 and 52–56 year-old women. Maturitas 2003; 46: 199–205
   PubMed Web of Science ®Google Scholar
• Feldman B M, Voda A, Gronseth E. The prevalence of hot flashes and associated variables among perimenopausal women. Res Nurs Health 1985; 8: 261–268
   PubMed Web of Science ®Google Scholar
• MacLennan A, Lester S, Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 2001; 4: 58–74
   PubMedGoogle Scholar
• Graeser T, Hoffmann H, Zimmermann H, et al. Lafamme®: A new oral preparation for continuous combined hormone replacement therapy in postmenopausal women. Drugs Today 2001; 37: 17–27
   Web of Science ®Google Scholar
• Graeser T, Koytchev R, Mueller A, et al. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest™ for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000; 3: 109–118
   PubMedGoogle Scholar
• Graeser T, Koytchev R, Roemer T, et al. Dienogest as a progestin for hormone replacement therapy. Drugs Today 1999; 35: 115–126
   Web of Science ®Google Scholar
• Hoffmann H, Felsch B, Mueller A, et al. Safety profile of a fixed formulation containing 2 mg estradiol valerate and 2 mg dienogest (Lafamme™) for continuous combined hormone replacement treatment in postmenopausal women. Drugs Today 2001; 37: 29–37
   Web of Science ®Google Scholar
• Oedmark I S, Backstrom T, Haeger M, et al. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. Maturitas 2004; 48: 137–146
   PubMed Web of Science ®Google Scholar
• Samsioe G, Li C R, Borgfeldt C, et al. Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17 beta-estradiol and norethisterone acetate. Menopause 2002; 9: 335–342
   PubMed Web of Science ®Google Scholar
• Graeser T, Roemer T, Wiedey K D, et al. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 2001; 4: 332–342
   PubMedGoogle Scholar
• Von Schoultz B. Clinical efficacy and safety of combined estradiol valerate and dienogest: A new no-bleed treatment. Climacteric 2003; 6/Suppl2: 24–32
   Google Scholar
• Ushiroyama T, Sakuma K, Ikeda A, et al. The HDL2/HDL3 ratio in menopause. Int J Gynaecol Obstet 2005; 88: 303–308
   PubMed Web of Science ®Google Scholar
• Oram J F. Effects of high density lipoprotein subfractions on cholesterol homeostasis in human fibroblasts and arterial smooth muscle cells. Arteriosclerosis 1983; 3: 420–432
   PubMedGoogle Scholar
• Manninen V, Tenkanen L, Koskinen P. Joint effects of serum triglycerides and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85: 37–45
   PubMed Web of Science ®Google Scholar
• Rubins H B, Robins S J, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–418
   PubMed Web of Science ®Google Scholar
• Vasan R S, Sullivan L M, Wilson P W, et al. Relative importance of borderline and elevated levels of coronary heart disease risk factors. Ann Intern Med 2005; 142: 393–402
   PubMed Web of Science ®Google Scholar
• Arai Y, Hirose N, Nakazawa S, et al. Lipoprotein metabolism in Japanese centenarians—Effects of apolipoprotein E polymorphism and nutritional status. J Am Geriatr Soc 2001; 49: 1434–1441
   PubMed Web of Science ®Google Scholar
• Oettel M, Graeser T, Hoffmann H. Why dienogest as a progestogenic component of postmenopausal nonandrogenic hormone replacement therapy. Drugs Today 2001; 37(Suppl G)3–15
   Google Scholar
• Wiegratz I, Lee J H, Kutschera E, et al. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception 2002; 65: 223–229
   PubMed Web of Science ®Google Scholar
• Kwok S, Selby P L, McElduff P, et al. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. Clin Endocrinol 2004; 61: 760–767
   PubMed Web of Science ®Google Scholar
• Arai Y, Hirose N. Aging and HDL metabolism in elderly people more than 100 years old. J Atheroscler Thromb 2004; 11: 246–252
   PubMedGoogle Scholar
• von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high density lipoprotein cholesterol?. Curr Opin Lipidol 2000; 11: 627–637
   PubMed Web of Science ®Google Scholar
• , et al. NIH Consensus Development Panel on Triglyceride, High Density Lipoprotein, and Coronary Heart Disease. JAMA 1993; 269: 505–510
   PubMed Web of Science ®Google Scholar
• Hulley S B, Rosenman R H, Bawol R D, et al. Epidemiology as a guide to clinical decisions. The association between triglycerides and coronary heart disease. N Engl J Med 1982; 302: 1383–1389
   Web of Science ®Google Scholar
• Post M S, Van Der Mooren M J, Van Baal W M, et al. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: A randomized placebo-controlled study. Am J Obstet Gynecol 2003; 189: 1221–1227
   PubMed Web of Science ®Google Scholar
• Thijs A, Stehouwer C D. Changes of hemostatic variables during hormone replacement therapy. Semin Vasc Med 2003; 3: 85–92
   PubMedGoogle Scholar
• Norris L A, Joyce M, O'Keeffe N, et al. Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 2002; 43: 125–133
   PubMed Web of Science ®Google Scholar
• Szymanski L M, Kessler C M, Fernhall B. Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women. J Appl Physiol 2005; 98: 1341–1348
   PubMed Web of Science ®Google Scholar
• Acs N, Vajo Z, Miklos Z, et al. The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies. Gynecol Endocrinol 2002; 16: 335–346
   PubMed Web of Science ®Google Scholar
• Jarret R J, Graver H J. Changes in oral glucose tolerance during the menstrual cycle. Br Med J 1968; 2: 528–529
   PubMed Web of Science ®Google Scholar